CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01609790
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:34.788191+00:00
Published At: 2017-02-27T00:00:00+00:00
Record Updated At: 2022-07-21
Results Posted At: 2017-02-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Giant Cell Glioblastoma", "Glioblastoma", "Gliosarcoma", "Oligodendroglioma", "Recurrent Brain Neoplasm", "Recurrent Glioblastoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-07-21"
protocolSection.identificationModule.nctId: "NCT01609790"
protocolSection.identificationModule.officialTitle: "Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2017-02-27"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.